VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

David Spigel, MD
Published: Saturday, Nov 01, 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

The two arms on this trial were similar — about 40% of patients on both arms were Asian. Most patients received gemcitabine or docetaxel.

The primary endpoint on this trial, overall survival, was not improved. Progression-free survival and response rates were similar between the two arms.

<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

The two arms on this trial were similar — about 40% of patients on both arms were Asian. Most patients received gemcitabine or docetaxel.

The primary endpoint on this trial, overall survival, was not improved. Progression-free survival and response rates were similar between the two arms.

<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x